Pediatric patients with psoriasis who experience a significant improvement in disease severity after treatment may experience the greatest positive impact to quality of life (QOL), finds a recent study from JAMA Dermatology.1
Investigators of the study, published in November 2019, also found that the type of treatment prescribed may play a role in QOL rating independent of disease severity.
It is well-known that psoriasis can negatively impact both adults and pediatric patients with the disease; however, the connection between degree of disease severity and improvement in QOL has not been as extensively studied in children with psoriasis as it has in adults with the condition.
“To our knowledge, this cohort study is the first to examine in a real-world setting the association between the degree of psoriasis improvement and quality of life in pediatric patients with psoriasis,” write the study authors.
The single-center cohort study analyzed data from 319 pediatric patients 18 years of age or younger stored in Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry). The individuals assessed received treatment in the outpatient clinic of the department of dermatology at the Radboud University Medical Center, Nijmegen, Netherlands, between Sept. 3, 2018 and March 4, 2018. Researchers used records of validated Children’s Dermatology Life Quality Index (CDLQI) scores, Psoriasis Area and Severity Index (PASI) scores and body surface area (BSA) scores in their analysis.
Treatment types were categorized as topical, dithranol, conventional systemic and biological therapy. The researchers note that cases which involved UV-B phototherapy were excluded due to low numbers.
1. Bruins FM, Bronckers IMGJ, Groenewoud HMM, et al. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients. JAMA Dermatol. 2019;
2. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64-70.